Linker Information
General Information of This Linker
| Linker ID |
LIN0OKZMX
|
|||||
|---|---|---|---|---|---|---|
| Linker Name |
DIBAC-PEG4-vcPAB
|
|||||
| Linker Type |
Cathepsin-cleavable linker
|
|||||
| Antibody-Linker Relation |
Cleavable
|
|||||
| Structure |
|
|||||
| Formula |
C57H83N11O16
|
|||||
| Isosmiles |
CC([C@H](NC(CCOCCOCCOCCOCCNC(CCC(N1CC2=C(C(NNN3CCOCCOCCOCCN)=C3C4=C1C=CC=C4)C=CC=C2)=O)=O)=O)C(N[C@@H](CCCNC(N)=O)C(NC5=CC=C(C=C5)COC(O)=O)=O)=O)C
|
|||||
| InChI |
InChI=1S/C57H83N11O16/c1-40(2)51(55(73)63-46(11-7-21-61-56(59)74)54(72)62-43-15-13-41(14-16-43)39-84-57(75)76)64-49(70)19-24-77-28-32-81-36-37-83-34-30-79-26-22-60-48(69)17-18-50(71)67-38-42-8-3-4-9-44(42)52-53(45-10-5-6-12-47(45)67)68(66-65-52)23-27-80-31-35-82-33-29-78-25-20-58/h3-6,8-10,12-16,40,46,51,65-66H,7,11,17-39,58H2,1-2H3,(H,60,69)(H,62,72)(H,63,73)(H,64,70)(H,75,76)(H3,59,61,74)/t46-,51-/m0/s1
|
|||||
| InChIKey |
AQTXBWONYHXSFN-YWHGXOANSA-N
|
|||||
| Pharmaceutical Properties |
Molecule Weight
|
1178.352
|
Polar area
|
356.29
|
||
|
Complexity
|
2473.210765
|
xlogp Value
|
1.9526
|
|||
|
Heavy Count
|
84
|
Rot Bonds
|
41
|
|||
|
Hbond acc
|
19
|
Hbond Donor
|
10
|
|||
Each Antibody-drug Conjugate Related to This Linker
Full Information of The Activity Data of The ADC(s) Related to This Linker
TRSQ-ZP3A- LP15-Vlh [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
0.044 nM
|
Positive HER2 expression (HER2+++/++) | ||
| Method Description |
The anti-proliferation test was carried out with SK-BR-3 human breast cancer cell line. Cells were grown in McCoy's 5a medium supplemented with 46% FBS,penicillin/streptomycin and L-glutamine.
|
||||
| In Vitro Model | Breast adenocarcinoma | SK-BR-3 cells | CVCL_0033 | ||
TRSQ-ZP3A- LP4-Ve [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
0.064 nM
|
Positive HER2 expression (HER2+++/++) | ||
| Method Description |
The anti-proliferation test was carried out with SK-BR-3 human breast cancer cell line. Cells were grown in McCoy's 5a medium supplemented with 32% FBS,penicillin/streptomycin and L-glutamine.
|
||||
| In Vitro Model | Breast adenocarcinoma | SK-BR-3 cells | CVCL_0033 | ||
TRSQ-ZP3A-LP13 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
0.083 nM
|
Positive HER2 expression (HER2+++/++) | ||
| Method Description |
The anti-proliferation test was carried out with SK-BR-3 human breast cancer cell line. Cells were grown in McCoy's 5a medium supplemented with 19% FBS,penicillin/streptomycin and L-glutamine.
|
||||
| In Vitro Model | Breast adenocarcinoma | SK-BR-3 cells | CVCL_0033 | ||
TRSQ-ZP3A-LP25 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
1.329 nM
|
Positive HER2 expression (HER2+++/++) | ||
| Method Description |
The anti-proliferation test was carried out with SK-BR-3 human breast cancer cell line. Cells were grown in McCoy's 5a medium supplemented with 29% FBS,penicillin/streptomycin and L-glutamine.
|
||||
| In Vitro Model | Breast adenocarcinoma | SK-BR-3 cells | CVCL_0033 | ||
TRSQ-ZP3A-LP20 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
1.366 nM
|
Positive HER2 expression (HER2+++/++) | ||
| Method Description |
The anti-proliferation test was carried out with SK-BR-3 human breast cancer cell line. Cells were grown in McCoy's 5a medium supplemented with 25% FBS,penicillin/streptomycin and L-glutamine.
|
||||
| In Vitro Model | Breast adenocarcinoma | SK-BR-3 cells | CVCL_0033 | ||
CTRL-ZP3A-LP4-Ve [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
23.401 nM
|
Positive HER2 expression (HER2+++/++) | ||
| Method Description |
The anti-proliferation test was carried out with SK-BR-3 human breast cancer cell line. Cells were grown in McCoy's 5a medium supplemented with 33% FBS,penicillin/streptomycin and L-glutamine.
|
||||
| In Vitro Model | Breast adenocarcinoma | SK-BR-3 cells | CVCL_0033 | ||